Literature DB >> 21073926

Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.

P Sokolowska1, S Passemard, A Mok, L Schwendimann, I Gozes, P Gressens.   

Abstract

Activity-dependent neuroprotective protein (ADNP) was shown to be essential for embryogenesis and brain development while NAP, an active motif of ADNP, is neuroprotective in a broad range of neurodegenerative disorders. In the present study, we examined the protective potential of ADNP/NAP in a mouse model of excitotoxic brain lesion mimicking brain damage associated with cerebral palsy. We demonstrated that NAP had a potent neuroprotective effect against ibotenate-induced excitotoxic damage in the cortical plate and the white matter of P5 mice, and moderate against brain lesions of P0 mice. In contrast, endogenous ADNP appears not to be involved in the response to excitotoxic challenge in the studied model. Our findings further show that NAP reduced the number of apoptotic neurons through activation of PI-3K/Akt pathway in the cortical plate or both PI-3K/Akt and MAPK/MEK1 kinases in the white matter. In addition, NAP prevented ibotenate-induced loss of pre-oligodendrocytes without affecting the number of astrocytes or activated microglia around the site of injection. These findings indicate that protective actions of NAP are mediated by triggering transduction pathways that are crucial for neuronal and oligodendroglial survival, thus, NAP might be a promising therapeutic agent for treating developing brain damage.
© 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073926     DOI: 10.1016/j.neuroscience.2010.10.074

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  10 in total

1.  Strategies to defeat ketamine-induced neonatal brain injury.

Authors:  C P Turner; S Gutierrez; C Liu; L Miller; J Chou; B Finucane; A Carnes; J Kim; E Shing; T Haddad; A Phillips
Journal:  Neuroscience       Date:  2012-02-23       Impact factor: 3.590

2.  ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment.

Authors:  Anna Malishkevich; Janina Leyk; Olaf Goldbaum; Christiane Richter-Landsberg; Illana Gozes
Journal:  J Mol Neurosci       Date:  2015-10       Impact factor: 3.444

3.  Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation.

Authors:  Joseph Levine; David Cohen; Carole Herman; Alain Verloes; Vincent Guinchat; Lautaro Diaz; Cora Cravero; Anne Mandel; Illana Gozes
Journal:  J Mol Neurosci       Date:  2019-07       Impact factor: 3.444

Review 4.  VIP-induced neuroprotection of the developing brain.

Authors:  Sandrine Passemard; Paulina Sokolowska; Leslie Schwendimann; Pierre Gressens
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Authors:  Avia Merenlender-Wagner; Zeev Shemer; Olga Touloumi; Roza Lagoudaki; Eliezer Giladi; Annie Andrieux; Nikolaos C Grigoriadis; Illana Gozes
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

Review 6.  Perinatal hypoxic-ischemic damage: review of the current treatment possibilities.

Authors:  A Frajewicki; Z Laštůvka; V Borbélyová; S Khan; K Jandová; K Janišová; J Otáhal; J Mysliveček; V Riljak
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

7.  Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.

Authors:  Michael Gold; Stefan Lorenzl; Alistair J Stewart; Bruce H Morimoto; David R Williams; Illana Gozes
Journal:  Neuropsychiatr Dis Treat       Date:  2012-02-09       Impact factor: 2.570

8.  Tau and caspase 3 as targets for neuroprotection.

Authors:  Anat Idan-Feldman; Regina Ostritsky; Illana Gozes
Journal:  Int J Alzheimers Dis       Date:  2012-05-30

9.  Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease.

Authors:  Ming-Hui Yang; Shih-Cheng Chen; Yu-Fen Lin; Yi-Chia Lee; Ming-Yii Huang; Ko-Chin Chen; Hsin-Yi Wu; Po-Chiao Lin; Illana Gozes; Yu-Chang Tyan
Journal:  J Food Drug Anal       Date:  2019-01-12       Impact factor: 6.157

10.  The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.

Authors:  Illana Gozes; Marc C Patterson; Anke Van Dijck; R Frank Kooy; Joseph N Peeden; Jacob A Eichenberger; Angela Zawacki-Downing; Sandra Bedrosian-Sermone
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-19       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.